Haematological Malignancies: News from ASH 2017

News and video reports on the research presented during ASH 2017 in Atlanta

Video reports

Reporting from ASH 2017 on Non-Hodgkin Lymphoma, Michele Ghielmini highlights the results of the NCI 9177 phase II study on DA-EPOCH-R in Burkitt's Lymphoma and studies presenting data on CAR-T cell therapy in relapsed/refractory DLBCL.


Reporting from ASH 2017 on Myeloma, Christian Buske highlights two studies relevant to clinical practice. EMNO2/HO95 compares ASCT to VMP showing superiority of ASCT; ALCYONE compares D-VMP to VMP with positive results for the additional of daratumumab.


Reporting from ASH 2017 on Hodgkin Lymphoma, Michele Ghielmini describes study results from Echelon-1, comparing AAVD with ABVD, and explains how interim PET was used to adjust the intensity of the treatment in the HD18 study.


Reporting from ASH 2017 on Chronic Lymphocytic Leukaemia, Christian Buske discusses studies investigating chemo-free approaches aiming to achieve MRD negativity and/or stopping treatment.  Increased MRD negativity was shown in MURANO with venetoclax+rituximab vs bendamustine+rituximab and in CLARITY with ibrutinib+venetoclax.

medwireNews articles (ESMO members)

Real-World CML Study Findings Support LeukemiaNet 2013 Response Monitoring Advice

18 Dec 2017, Interim results from the TARGET UK Study of chronic myeloid leukaemia confirm the benefit of early and frequent monitoring of patient response to tyrosine kinase inhibitor therapy...
Read the article

Edoxaban Noninferior To Dalteparin For Recurrent VTE Prevention In Cancer Patients

15 Dec 2017, For cancer patients with venous thromboembolism, the direct oral anticoagulant edoxaban is noninferior to low molecular weight heparin for the prevention of recurrent events and major bleeding...
Read the article

Daratumumab Boosts First-Line Multiple Myeloma Regimen’s Efficacy

14 Dec 2017, Combining daratumumab with bortezomib, melphalan and prednisone significantly improves progression-free survival for patients with newly diagnosed...
Read the article

CAR T-Cell Therapy Induces ‘Durable Response’ In Refractory Large B-Cell Lymphoma Patients

13 Dec 2017, ZUMA-1 findings indicate that axicabtagene ciloleucel is feasible and effective for the treatment of relapsed or refractory diffuse large B-cell lymphoma...
Read the article